Early Morning Activity Shows AstraZeneca (AZN) Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified AstraZeneca ( AZN) as a pre-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified AstraZeneca as such a stock due to the following factors:

  • AZN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $273.6 million.
  • AZN traded 13,443 shares today in the pre-market hours as of 7:32 AM.
  • AZN is down 2.7% today from yesterday's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in AZN with the Ticky from Trade-Ideas. See the FREE profile for AZN NOW at Trade-Ideas

More details on AZN:

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. The stock currently has a dividend yield of 3.9%. AZN has a PE ratio of 35.6. Currently there is 1 analyst that rates AstraZeneca a buy, 1 analyst rates it a sell, and 4 rate it a hold.

The average volume for AstraZeneca has been 4.2 million shares per day over the past 30 days. AstraZeneca has a market cap of $91.7 billion and is part of the health care sector and drugs industry. Shares are up 24.1% year-to-date as of the close of trading on Monday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting

AstraZeneca Spikes After Lung Cancer Treat Study Shows 'Encouraging' Results